CAR-T Cell Therapy for Lymphoma: What to Expect

Research-informed explainer — last updated April 12, 2026

CAR-T cell therapy is a form of immunotherapy that reprograms your own immune cells to recognize and attack lymphoma. For patients with certain aggressive B-cell lymphomas that have come back after two or more prior treatments, it has produced complete remissions in a meaningful fraction of people who had few other options. The procedure itself is more involved than a standard infusion — it takes several weeks from start to finish and requires close monitoring at a specialized center.

This article walks through how CAR-T works, who qualifies, what the treatment timeline actually looks like, and what clinical data show about outcomes. It draws on research from three hematology specialists in the Convene directory who practice at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

What is CAR-T cell therapy?

CAR-T stands for chimeric antigen receptor T-cell therapy. It starts with your own T cells — the immune cells that normally hunt down infections and abnormal cells. In a laboratory, those T cells are modified with a synthetic receptor that tells them to target a specific protein on the surface of lymphoma cells, most commonly CD19.

Once the modified cells are infused back into your body, they multiply and go to work attacking the cancer. The approach differs from chemotherapy, which kills rapidly dividing cells broadly, and from antibody drugs, which attach to cancer cells from the outside. CAR-T cells are living therapy that can persist in the body for months or years.

How the procedure works

Step 1: Apheresis (collecting your T cells)

The process starts with leukapheresis, a procedure where your blood passes through a machine that separates out T cells and returns the rest to you. It typically takes three to five hours and is done at a certified apheresis center. You may feel cold or have some tingling, but most patients tolerate it well.

Step 2: Cell manufacturing

Your collected T cells are shipped to a manufacturing facility, where they are genetically modified and expanded. This step takes two to four weeks depending on which CAR-T product is being made. During this time your team may give you bridging chemotherapy — a lower-intensity regimen to keep the lymphoma from progressing while you wait.

Step 3: Lymphodepleting chemotherapy

A few days before the CAR-T infusion, you receive a short course of chemotherapy, usually fludarabine and cyclophosphamide. This is sometimes called conditioning or lymphodepletion. Its purpose is to clear space in your immune system so the engineered T cells can multiply more effectively once infused.

Step 4: CAR-T infusion

The actual infusion takes less than an hour. The engineered cells are given through an IV line, similar to how other blood products are administered. This is the shortest part of the process — the weeks of preparation before it are the heavier lift.

Step 5: Inpatient monitoring

Most centers require patients to stay in or near the hospital for at least a week after infusion, sometimes longer. This is because the most serious side effects — cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome — typically appear within the first two weeks. Your team will monitor your temperature, blood pressure, neurological status, and lab values closely during this window.

Who is a candidate?

Current FDA-approved CAR-T products for lymphoma target patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and related subtypes. The approved indications vary by product, but generally require that the lymphoma has returned or not responded after two or more prior lines of therapy.

More recently, two CAR-T products received approval for second-line use in patients whose lymphoma came back within 12 months of first-line treatment or who were not candidates for autologous stem cell transplant. This represents a significant expansion of eligibility.

Patients generally need to be fit enough to tolerate the procedure, have adequate organ function, and be able to comply with the monitoring requirements. Your hematologist will review your prior treatments, the biology of your lymphoma, and your overall health before recommending CAR-T. The evaluation includes restaging scans, bone marrow biopsy in some cases, and assessments of heart, kidney, and liver function.

For patients with B-cell lymphoid malignancies who are not candidates for CAR-T, targeted options continue to expand — research from Dana-Farber has shown durable responses with antibody-drug conjugates and BTK inhibitors in specific lymphoma subtypes [1][3], and novel immunotargeted agents have produced high remission rates in relapsed B-cell cancers [4].

Risks and recovery

Cytokine release syndrome (CRS)

The most common serious side effect is cytokine release syndrome, which happens when activated CAR-T cells release large amounts of inflammatory proteins. Symptoms range from fever and flu-like aches to low blood pressure, difficulty breathing, and in severe cases, organ stress. Most CRS is manageable with tocilizumab, an IL-6 blocking antibody, and steroids. Severe CRS occurs in a minority of patients and is most likely to develop in the first two weeks.

Neurologic toxicity (ICANS)

A subset of patients develop neurologic symptoms including confusion, difficulty finding words, tremor, or in rare cases seizures. This side effect — called immune effector cell-associated neurotoxicity syndrome (ICANS) — is also most common in the first week or two and usually resolves with corticosteroids. Your care team will have you perform simple cognitive tests daily during this period to catch changes early.

Prolonged low blood counts

Lymphodepleting chemotherapy and the inflammatory response can suppress the bone marrow for weeks. Low white blood cell counts increase infection risk, and patients often need growth factor injections and transfusions during recovery. This phase is managed in part by close outpatient follow-up after the initial hospital stay.

Long-term B-cell aplasia

Because most CAR-T products target CD19, which is present on healthy B cells as well as lymphoma cells, the therapy can eliminate normal B cells for months or years. This leads to low immunoglobulin levels and increased susceptibility to infections. Many patients receive monthly immunoglobulin infusions (IVIG) as replacement therapy.

Research on clonal changes in the blood-forming stem cells — including work examining what happens to bone marrow after intensive prior therapies like autologous transplant — informs how centers monitor for delayed marrow complications in patients who eventually receive CAR-T after prior transplant [2].

What research shows

The two landmark trials that established CAR-T for large B-cell lymphoma used products approved in the United States:

Axicabtagene ciloleucel (axi-cel, Yescarta) was studied in the ZUMA-1 trial in heavily pretreated patients with refractory large B-cell lymphoma. Overall response rates were high, with a substantial fraction of patients achieving complete remission. The ZUMA-1 long-term data showed that patients who achieved complete remission had durable responses, with some remaining progression-free years later — a meaningful finding in a population where median survival historically measured in months.

Tisagenlecleucel (tisa-cel, Kymriah) showed similar findings in the JULIET trial, with durable complete responses in a portion of adult patients with relapsed or refractory DLBCL.

When CAR-T was moved earlier — to second-line treatment in patients with early relapse — randomized trials comparing it against standard salvage chemotherapy followed by autologous stem cell transplant showed a significant advantage in event-free survival for CAR-T, supporting the expanded indications that followed.

The broader context of treating aggressive lymphomas has been shaped by research showing that targeted approaches — antibody-drug conjugates, next-generation kinase inhibitors, and immunotherapies — can extend remissions in patients across different lymphoma subtypes when prior regimens have failed [1][3][4][5].

What specialists are discovering

Research interest is now focused on two fronts. First, how to predict which patients are most likely to respond — factors like baseline tumor burden, inflammatory markers before infusion, and T-cell fitness at the time of collection all appear to influence outcomes. Second, how to make CAR-T work in lymphoma subtypes and settings where it has not yet been approved, including follicular lymphoma, mantle cell lymphoma, and T-cell lymphomas.

Combination approaches pairing CAR-T with checkpoint inhibitors or bispecific antibodies are in clinical trials. And off-the-shelf allogeneic CAR-T products — made from donor cells rather than a patient's own cells — aim to eliminate the manufacturing wait and reduce cost, though none are yet approved for lymphoma in the United States.

The expanding toolkit for lymphoid cancers — from ibrutinib combinations in Waldenström macroglobulinemia [8] to IDH inhibitors in related myeloid diseases [6] — reflects the same precision-medicine logic driving CAR-T development: match therapy to the biology of each patient's cancer rather than defaulting to chemotherapy alone.

Questions to ask your doctor

• Is my lymphoma subtype and treatment history consistent with the eligibility criteria for an approved CAR-T product?
• Which CAR-T product would you recommend for me, and how does your center's experience with it compare to the trial data?
• What happens if my lymphoma progresses during the manufacturing wait? What bridging therapy would you use?
• How long will I need to stay near the treatment center after infusion, and what restrictions apply?
• What is your center's rate of grade 3 or higher CRS, and how do you manage it?
• After CAR-T, will I need immunoglobulin replacement therapy, and for how long?
• If CAR-T doesn't produce a remission, what would the next step be?

The bottom line

CAR-T cell therapy has changed the outlook for patients with relapsed or refractory large B-cell lymphoma who have limited options after multiple prior treatments. The procedure is intensive — a multi-week process that requires careful preparation, a short hospital stay, and close monitoring — but it offers the possibility of durable complete remission in a disease that was historically very difficult to control. Eligibility has expanded in recent years to include some second-line patients.

Whether you are a candidate depends on your lymphoma subtype, your prior treatment history, your overall fitness, and how quickly your lymphoma is moving. The conversation starts with a referral to a center that performs CAR-T and a formal evaluation by a specialist in aggressive lymphomas.